LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

NCT01271725 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Vinorelbine 25 mg/m2 weekly
DRUG: Afatinib 40mg once daily (OD)
DRUG: Paclitaxel 80 mg/m2 weekly

Sponsor

Boehringer Ingelheim